

Identification and genetic characterization of metallo-beta-lactamase-producing strains of *Pseudomonas aeruginosa* in Tehran, Iran

Fereshteh Shahcheraghi¹, Vajiheh Sadat Nikbin¹, Mohammad Mahdi Feizabadi²

¹Department of Bacteriology, Pasteur Institute of Iran, Tehran, Iran;

²Department of Microbiology, School of Medicine, Tehran University of Medical Science

SUMMARY

Metallo-beta-lactamases (MBLs) are being reported with increasing frequency worldwide. The aim of this study was to investigate the prevalence of *bla*_{IMP-1}, *bla*_{VIM-1,2} and *bla*_{SPM-1} genes encoding metallo-beta-lactamases (MBLs) among a collection of *Pseudomonas aeruginosa* strains isolated from patients at different hospitals in Tehran and to trace the disseminated clones at these hospitals by pulsed field gel electrophoresis (PFGE). Susceptibility of 610 *P. aeruginosa* to 14 different antibiotics was determined using disc diffusion method. Isolates showing resistance to imipenem and ceftazidime were subjected to micro broth dilution assay to determine their MIC values. The *bla*_{IMP-1}, *bla*_{VIM-1}, *bla*_{VIM-2} and *bla*_{SPM-1} genes were amplified by PCR. Isolates containing *bla*_{VIM-1} were analyzed by PFGE. Sixty-eight isolates were resistant to imipenem (MIC ≥ 4 $\mu\text{g/ml}$) of which 16 isolates carried *bla*_{VIM-1} gene using PCR assay. No other MBL genes were detected in this study. Three different unrelated patterns were found for isolates containing *bla*_{VIM-1} gene by PFGE of which pattern A was predominant. All isolates were susceptible to colistin and polymixin B. *bla*_{VIM-1} was the main gene encoding MBL among the isolates of *P. aeruginosa* in our study. Clonal spread of isolates containing *bla*_{VIM-1} had occurred at Tehran hospitals. However, heterogeneous clones also were involved in the outbreaks.

KEY WORDS: *Pseudomonas aeruginosa*, Metallo- β -lactamases, VIM, IMP, SPM

Received September 09, 2009

Accepted February 03, 2010

INTRODUCTION

Pseudomonas aeruginosa is an opportunistic pathogen associated with a range of nosocomial infections. Carbapenems, including meropenem and imipenem, are the most effective antibiotic against this organism isolated from patients. However, resistance to carbapenems has emerged by different mechanisms such as impermeability to drug due to loss of OprD porin, the up-regulation of an active efflux pump system present in the cytoplasmic membrane of these organisms or production of metallo-beta-lactamases (MBLs)

that hydrolyze all carbapenems (Kohler *et al.*, 1999; Livermore *et al.*, 1992; Nordmann and Poirel, 2002). Increases in prevalence of carbapenem resistance mediated by acquired MBLs including, IMP and VIM have been reported from several countries (Iseri *et al.*, 2008; Picao *et al.*, 2009; Kouda *et al.*, 2009; Mansour *et al.*, 2009). However, the prevalence of MBL producing isolates of *P. aeruginosa* varies in Asian countries (Walsh *et al.*, 2002).

The most common and widespread acquired MBLs are those of the IMP and VIM types, which exhibit a worldwide distribution and for which several allelic variants are known. Acquired drug resistance is frequent in nosocomial isolates of *P. aeruginosa* and often involves more than one antibiotic class (Poirel *et al.*, 2001; Rossolini and Mantengoli, 2005).

Previous studies showed the high prevalence of multidrug resistant *P. aeruginosa* isolated from

Corresponding author

Dr. Fereshteh Shahcheraghi

Department of Bacteriology

Pasteur Institute of Iran

Pasteur Street, Postal code: 13164, Tehran, Iran

E-mail: shahcheraghifereshteh@yahoo.com

Shahcheraghi@pasteur.ac.ir

different clinical specimens especially from burn units in Iran (Shahcheraghi *et al.*, 2003; Shahcheraghi *et al.*, 2009). However, little information is available on the distribution of MBL-producing isolates and clonal infections with these isolates in our country. The aims of this study were to determine the prevalence of *bla*_{IMP-1}, *bla*_{VIM-1,2} and *bla*_{SPM-1} genes encoding MLBs among *P. aeruginosa* isolated from clinical specimens at different hospitals in Tehran and to investigate possible clonal dissemination of these organisms by PFGE.

MATERIALS AND METHODS

Bacterial strains

Six hundred and ten isolates of *P. aeruginosa* were collected from two hospitals in Tehran during June 2005–March 2007. The specimens included urine (n=153, 25%), blood (n= 27, 4%), wound (n=129, 22%), respiratory tract (n=176, 29%), Cerebral Spinal Fluid (n=4, 0.6%), ear (n=8, 1.3%), eye (n=16, 2.6%), stool (n=44, 7%) and other sites (n=53, 9%). These isolates were collected from different wards including ICU, urology, respiratory and surgery wards. Replicated isolates from the same patients were excluded from the study. All isolates were identified by conventional bacteriological tests.

Antibiotic susceptibility testing

Antibiotic susceptibility testing was performed as recommended by the Clinical and Laboratory Standards Institute (CLSI) (M100-S16 CLSI, 2006) using disks containing ceftazidime (CAZ:30 µg), ceftriaxone (CRO:30 µg), cefotaxime (CTX:30 µg), ceftizoxime (ZOX:30 µg), piperacilin (PIP:100 µg), piperacilin/tazobactam (PT:110 µg), gentamicin (GM:10 µg), amikacin (AN:30 µg), imipenem (IMP:10 µg), ciprofloxacin (CIP:5 µg) collistin (COL:10 µg), polymixin B (PB:300 unit), meropenem (MEM:10 µg) and aztreonam (ATM: 30 µg) (MAST, Merseyside, U.K). *Escherichia coli* ATCC 25922 and *P. aeruginosa* ATCC 27853 were used as controls for antibiotic resistance. MICs for ceftazidime and imipenem were determined by micro broth dilution method.

Identification of metallo-beta lactamases

Double disk synergy test (DDST) was used for

phenotypic detection of MBLs (Pitout *et al.*, 2005). In brief, disks containing 930 µg of EDTA plus 10 µg of imipenem were placed on the inoculated plates containing Muller Hinton agar. An increase of ≥7 mm in zone diameter in the presence of 930 µg of EDTA compared to imipenem tested alone was considered to be a positive test for the presence of an MBL.

DNA template from imipenem resistant isolates (MIC≥4 µg/ml) were extracted by boiling for 15 minutes and used in PCR to amplify *bla*_{VIM-1}, *bla*_{VIM-2}, *bla*_{SPM-1} and *bla*_{IMP-1} genes (Shibata *et al.*, 2003). PCR were carried out in solution containing 200 µM concentrations of dNTPs, 10 pM of each primer, 0.8 mM MgCl₂, 0.5 U Taq polymerase and 50 ng DNA templates in a final volume of 25 µL.

The mentioned genes were amplified under following condition: initial denaturation at 94°C for 2 min, followed by 30 cycles of denaturation at 94°C for 1 min, annealing at 55°C for 1 min and extension at 72°C for 1 min and final extension at 72°C for 10 min. *Acinetobacter baumannii* AC54/97 producing *bla*_{IMP} gene (Gombac *et al.*, 2002), *P. aeruginosa* PO510 producing *bla*_{VIM-1}, *P. aeruginosa* COL-1 producing *bla*_{VIM-2} and *P. aeruginosa* 16 producing *bla*_{SPM-1} (Kindly provided by P. Nordmann) were used as controls.

The amplicons were electrophoresed in 1% agarose gel and visualized after staining with ethidium bromide. A 100 bp ladder (Fermentas, Vilnius, Lithuania) was used as molecular weight marker. The PCR products for *bla*_{VIM-1} were purified on Qiaquick columns (QIAGEN) and the sequencing was carried out using the ABI capillary system (Macrogen Research, Seoul, Korea).

PFGE analysis

The intact chromosomal DNAs from VIM-1-producing and non-producing strains (MIC≥4 µg/ml) were extracted for PFGE as described previously (Nikbin *et al.*, 2007). The genomic DNA in agarose plugs were digested with *Xba*I restriction endonuclease (Fermentas, Vilnius, Lithuania) and the fragments were separated by CHEF-DR III apparatus (Bio-Rad Laboratories, Richmond, CA). The system was set up at 6 V/cm for 19 h with pulse time ramped from 5 to 35s. *Salmonella braenderup* H9812 used as molecular weight Marker. The gels were stained with ethidium bromide and DNA patterns were photographed with

UVP gel Documentation (UVP, UK) (Figure 1). The DNA banding patterns were interpreted as instructed by Tenover *et al.* (Tenover *et al.*, 1995).

Nucleotide Sequencing

The nucleotide sequences of amplicons have been assigned to the Gene Bank under accession numbers FJ226585 and FJ355956-355963. Aligning of the obtained sequences with those of reference strains in Gene Bank confirmed the correct identification of *bla*_{VIM-1} by PCR.

RESULTS

Of the total 610 *P. aeruginosa* collected in this study 76 isolates were found resistant to imipenem by disk diffusion test. The majority of these resistant isolates (n=65, 85.5%) belong to a general hospital and the remainder (n=11, 14.5%) to a children hospital. Of these 76 imipenem resistant isolates, 68 isolates showed MIC \geq 4 μ g/ml for imipenem. Based on the results of DDST, 72% of these isolates were positive for production of MBL and 28% of them were MBL negative. The rate of resistance in MBL positive/negative isolates to the antibiotic were as follows: amikacin (73/87), gentamicin (81/88), imipenem (100/100), ceftazidime (100/100), ceftriaxone (100/100), piperacilin (85/100), piperacilin/tazobactam (75/100) and ciprofloxacin (70/66). All imipenem resistant isolates in this study were susceptible to colistin and polymixin B.

The rate of resistance to antibiotics and MIC values for imipenem did not show significant difference among the isolates collected over the time of this research.

The results of PCR assay for 68 isolates showing MIC \geq 4 μ g/ml for imipenem showed that only sixteen isolates (32% MIC \geq 8 μ g/ml) harbored *bla*_{VIM-1} gene from which four isolates were negative and twelve were positive in double disk synergy test for MBL. These 16 strains were isolated from patients in a general (15 strains) and a children hospital and were cultured from wound (n=5) and tracheal aspirates (n=11) (Table 1). No *bla*_{IMP-1}, *bla*_{SPM-1} and *bla*_{VIM-2} genes were detected among imipenem resistant strains in this study.

All of the *bla*_{VIM-1} positive isolates were multi resistant to aztreonam, ceftazidime, ceftriaxone, ceftaxime, ceftizoxime, piperacilin, piperacilin/




FIGURE 1 - The PFGE patterns of VIM-1 producing isolates after digestion of genomic DNA with *Xba* I. Lane 4 and 10: *S. braenderup* H9812 as molecular weight Marker. lane 1: IM-596, lane 2 and 3: IM-699 and IM-653, lane 5: IM-562, lane 6, 7, 8, 9: IM-527, 546, 684 and MT-1205. lane 11, 12, 14: IM-607, 613, 556. lane 13: IM-549.

tazobactam, gentamicin, amikacin, imipenem, ciprofloxacin. Only one isolate showed susceptibility to ciprofloxacin and gentamicin and one isolate was susceptible to meropenem (Table 1).

PFGE analysis

The sixteen VIM-1-producing *P. aeruginosa* isolates belong to three different unrelated patterns based on the criteria explained by Tenover *et al.*, (Tenover *et al.*, 1995) (Figure 1). These patterns were allocated as A to C (Table 1). With the exception of an isolate within pattern C (Isolate IM-596), the remaining 15 isolates were resistant to ciprofloxacin and gentamicin. Pattern A also found among at least five isolates lacking *bla*_{VIM-1} gene.

DISCUSSION

During the last decade, several MBL enzymes have been identified in *P. aeruginosa*, beginning with IMP-1 and its derivatives, which are widespread in Japan and China (Senda *et al.*, 1996; Chu *et al.*, 2001).

They are also emerging in Europe and Canada (Nordmann *et al.*, 2002; Gibb *et al.*, 2002). The VIM-1 and VIM-2 enzymes are also highly prevalent in Korea (88%) and Greece (85%) (Oh *et al.*,

Table 1 - Phenotypic characteristics and PFGE patterns of 16 *P. aeruginosa* isolates carrying *bla*_{VIM-1} gene.

Name of isolate	Source of isolate	MIC _{CAZ}	MIC _{IMP}	MEM	DDST (EDTA+IMP)	PFGE pattern
IM-527	Tracheal	256	16	R	+	A
IM-546	Wound	256	16	R	+	A
IM-549	Wound	512	16	R	-	A
IM-556	Wound	512	16	R	+	A
IM-562	Wound	64	16	S	+	A
IM-607	Tracheal	16	16	R	+	A
IM-613	Tracheal	16	16	R	-	A
IM-684	Tracheal	16	16	R	-	A
IM-691	Sputum	256	16	R	+	A
IM-694	Tracheal	512	32	R	+	A
IM-695	Tracheal	256	8	R	+	A
IM-702	Tracheal	512	16	R	+	A
MT-1205	Tracheal	32	32	R	-	A
IM-653	Tracheal	32	32	R	+	B
IM-699	Wound	512	32	R	+	B
IM-596	Tracheal	16	32	R	+	C

2003; Giakkoupi *et al.*, 2003). Previous investigations indicated that IMP and VIM types of MBLs are also widespread in Asian countries (Yan *et al.*, 2001, Yatsuyanagi *et al.*, 2004). VIM type is also the most prevalent enzyme in our neighboring country, Turkey (Strateva and Yordanov 2009). The emergence of multidrug resistant strains of *P. aeruginosa* is a serious concern especially in burns patients who are hospitalized in Tehran (Shahcheraghi *et al.*, 2003).

In this study, *P. aeruginosa* strains (n=610) showed a multidrug resistance phenotype though imipenem, ciprofloxacin and amikacin were most effective antibiotics respectively. Fortunately, in spite of increasing resistance to imipenem in *P. aeruginosa* isolated from other countries, the rate of resistance to imipenem appears not to be high in Tehran hospitals (11%).

This may be due to limitations in the prescription of this carbapenem since it is solely admin-

istered in hospitals. In a previous study in Iran (Khosravi and Mihani 2008), like our findings, only *bla*_{VIM} gene was detected among the isolates and no MBL-producing isolates were positive for *bla*_{IMP} gene by PCR.

However, the rate of *bla*_{VIM-1} gene among the imipenem resistant strains tested in this study and resistance of these strains to all tested antibiotics should be considered.

Importantly, these resistant strains showed low level of resistance to imipenem (MIC \leq 32 μ g/ml) but most of them showed a high level of resistance to ceftazidime (Table 1) and all of them were susceptible to collistin and polymixin B.

Metallo- β -lactamases can hydrolyze all beta-lactams except aztreonam but our study showed that all MBL-producing isolates were resistant to aztreonam.

This could be due to existence of other mechanisms such as ESBL production, efflux pumps

and cephalosporinase hyperproduction (Walsh *et al.*, 2002).

Molecular typing by PFGE disclosed three different unrelated patterns among VIM-1-producing strains.

It also showed that VIM negative *P. aeruginosa* strains may belong to pattern A that was the dominant pattern observed in VIM-1-producing strains (VIM negative data not shown). The results of PFGE also suggest that VIM-1 positive strains were likely derived from a clonal lineage that was already circulating in the nosocomial setting upon acquisition of the *bla*_{VIM-1} determinant. As *bla*_{VIM-1} is located on mobile elements (Lauretti *et al.*, 1999), dissemination of *bla*_{VIM-1} could be due to both movement of resistance genes and clonal dissemination of the resistant strains.

As MBL genes are located on mobile genetic cassettes with other resistance determinants inserted into integrons (Nordmann *et al.*, 2002; Bush, 2001; Livermore and Woodford, 2000), the isolates of *P. aeruginosa* producing these enzymes often exhibit resistance to additional classes of drugs and behave as multi-resistant. Our data also demonstrated that most of VIM-1-producing strains are resistant to aminoglycosides and to fluoroquinolones.

In conclusion, the results obtained in the present study indicated that VIM-1 is the only MBL enzyme to emerge among clinical isolates of *P. aeruginosa* in our country to date. As patients with infections caused by MBL-producing organisms are at an increased risk of treatment failure, rapid identification of these organisms is essential and care should be taken to use imipenem just in critical conditions. So, it is recommended that a simple test based on CLSI recommendation should be adopted to confirm MBL-producing bacteria in clinical laboratories.

Acknowledgments:

This study was supported by grants from the Pasteur Institute of Iran. The authors thank Fahimeh Shooraj, Morvarid Shafei and Hanieh Noveiri for their technical assistance and also the members of clinical microbiology laboratories, Emam Khomeini and Markaze Tebbi Koodakan hospitals for their cooperation. We are also very grateful to Professor Nordmann and Cristina Lagatolla for providing us standard strains for the PCR assay.

REFERENCES

- CHU Y.W., AFZAL-SHAH M., HOUANG E.T., PALEPOU M.I., LYON D.J., WOODFORD N., LIVERMORE D.M. (2001). IMP-4, a novel metallo- β -lactamase from nosocomial *Acinetobacter* spp. collected in Hong Kong between 1994 and 1998. *Antimicrob. Agents. Chemother.* **45**, 710-714.
- CLINICAL AND LABORATORY STANDARDS INSTITUTE. (2006). Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. Approved standard document M7-A7. CLSI, Wayne, PA.
- GIAKKOUPIS P., PETRIKOS G., TZOUVELEKIS L.S., TSONAS S., LEGAKIS N.J., VATOPOULOS A.C. AND THE WHONET GREECE STUDY GROUP. (2003). Spread of integron-associated VIM-type metallo- β -lactamase genes among imipenem nonsusceptible *Pseudomonas aeruginosa* strains in Greek hospitals. *J. Clin. Microbiol.* **41**, 822-825.
- GIBB A.P., TRIBUDDHARAT C., MOORE R.A., LOUIE T.J., KRULICKI W., LIVERMORE D.M., PALEPOU M.F.I., WOODFORD N. (2002). Nosocomial outbreak of carbapenem-resistant *Pseudomonas aeruginosa* with a new *bla*_{IMP} allele, *bla*_{IMP-7}. *Antimicrob. Agents. Chemother.* **46**, 255-258.
- GOMBAC F., RICCIO M.L., ROSSOLINI G.M., LAGATOLLA C., TONIN E., MONTI-BRAGADIN C., LAVENIA A., DOLZANI L. (2002). Molecular characterization of integrons in epidemiologically unrelated clinical isolates of *Acinetobacter baumannii* from Italian hospitals reveals a limited diversity of gene cassette arrays. *Antimicrob. Agents. Chemother.* **46**, 3665-3668.
- IŞERI L., BAYRAKTAR M.R. (2008) Changes in the rates of antimicrobial resistance among clinical isolates of *Pseudomonas aeruginosa* between 2002 and 2004 in a tertiary-care teaching hospital in Turkey. *New. Microbiol.* **31**, 351-355.
- KHOSRAVI A.D., MIHANI F. (2008). Detection of metallo- β -lactamase-producing *Pseudomonas aeruginosa* strains isolated from burn patients in Ahwaz, Iran. *Diagn. Microbiol. Infect. Dis.* **60**, 125-128.
- KOHLER T., MICHEA-HAMZEPPOUR M., EPP S.F., PECHERE J.C. (1999). Carbapenem activities against *Pseudomonas aeruginosa*: respective contributions of OprD and efflux systems. *Antimicrob. Agents. Chemother.* **43**, 424-427.
- KOUDA S., OHARA M., ONODERA M., FUJIE Y., SASAKI M., KOHARA T., KASHIYAMA S., HAYASHIDA S., HARINO T., TSUJI T., ITAHA H., GOTOH N., MATSUBARA A., USUI T., SUGAI M. (2009). Increased prevalence and clonal dissemination of multidrug-resistant *Pseudomonas aeruginosa* with the *bla*_{IMP-1} gene cassette in Hiroshima. *J. Antimicrob. Chemother.* **64**, 46-51.
- LAURETTI L., RICCIO M.L., MAZZARIOL A., CORNAGLIA G., AMICOSANTE G., FONTANA R., ROSSOLINI G.M. (1999). Cloning and characterization of *bla*_{VIM}, a new integron-borne metallo- β -lactamase gene from a

- Pseudomonas aeruginosa* clinical isolate. *Antimicrob. Agents. Chemother.* **43**, 1584-1590.
- LIVERMORE D.M. (1992). Interplay of impermeability and chromosomal beta-lactamase activity in imipenem-resistant *Pseudomonas aeruginosa*. *Antimicrob. Agents. Chemother.* **36**, 2046-2048.
- MANSOUR W., POIREL L., BETTAIEB D., BOUALLEGUE O., BOUJAAFAR N., NORDMANN P. (2009). Metallo-beta-lactamase producing *Pseudomonas aeruginosa* isolates in Tunisia. *Diagn. Microbiol Infect. Dis.* **64**, 458-461.
- NIKBIN V.S., ABDI-ALI A., FEIZABADI M.M., GHARAVI S. (2007). Pulsed field gel electrophoresis & plasmid profile of *Pseudomonas aeruginosa* at two hospitals in Tehran, Iran. *Indian. J. Med. Res.* **126**, 146-151.
- NORDMANN P., POIREL L. (2002). Emerging carbapenemases in Gram-negative aerobes. *Clin. Microbiol. Infect.* **8**, 321-331.
- OH E.J., LEE S., PARK Y.J., PARK J.J., PARK K., KIM S.I., KANG M.W., KIM B.K. (2003). Prevalence of metallo-β-lactamase among *Pseudomonas aeruginosa* and *Acinetobacter baumannii* in a Korean University hospital and comparison of screening methods for detecting metallo-β-lactamase. *J. Microbiol. Methods.* **54**, 411-418.
- PICAO R.C., POIREL L., GALES A.C., NORDMANN P. (2009). Diversity of β-Lactamases produced by ceftazidime-resistant *Pseudomonas aeruginosa* isolates causing bloodstream infections in Brazil. *Antimicrob. Agents. Chemother.* **53**, 3908-3913.
- PITOUT J.D.D., GREGSON D.B., POIREL L., MCCLURE J., LE P., CHURCH D.L. (2005). Detection of *Pseudomonas aeruginosa* Producing Metallo-β-Lactamases in a Large Centralized Laboratory. *J. Clin. Microbiol.* **43**, 3129-3135.
- POIREL L., LAMBERT T., TURKOGLU S., RONCO E., GAILLARD J., NORDMANN P. (2001). Characterization of class 1 integrons from *Pseudomonas aeruginosa* that contain the *bla*_{VIM-2} carbapenem-hydrolyzing β-lactamase gene and of two novel aminoglycoside resistance gene cassettes. *Antimicrob. Agents. Chemother.* **45**, 546-552.
- ROSSOLINI G.M., MANTENGOLI E. (2005). Treatment and control of severe infections caused by multiresistant *Pseudomonas aeruginosa*. *Clin. Microbiol. Infect.* **11**, 17-32.
- SENDA K., ARAKAWA Y., ICHIYAMA S., NAKASHIMA K., ITO H., OHSUKA S., SHIMOKATA K., KATO N., OHTA M. (1996). PCR detection of metallo-β-lactamase gene (*bla*_{IMP}) in gram-negative rods resistant to broad-spectrum β-lactams. *J. Clin. Microbiol.* **34**, 2909-2913.
- SHAHCHERAGHI F., FEIZABADI M.M., YAMIN V., ABIRI R., ABEDIAN Z. (2003). Serovar determination, drug resistance patterns and plasmid profiles of *Pseudomonas aeruginosa* isolated from burn patients at two hospitals of Tehran (IRAN). *Burns.* **29**, 547-551.
- SHAHCHERAGHI F., NIKBIN V.S., FEIZABADI M.M. (2009). Prevalence of ESBLs genes among multi drug resistant isolates of *Pseudomonas aeruginosa* isolated from patients in Tehran. *Microbial. Drug. Resistance.* **15**, 37-39.
- SHIBATA N., DOI Y., YAMANE K., YAGI T., KUROKAWA H., SHIBAYAMA K., KATO H., KAI K., ARAKAWA Y. (2003). PCR typing of genetic determinants for metallo-β-lactamases and integrases carried by gram-negative bacteria isolated in Japan, with focus on the class 3 integron. *J. Clin. Microbiol.* **41**, 5407-5413.
- STRATEVA T., YORDANOV D. (2009). *Pseudomonas aeruginosa* - a phenomenon of bacterial resistance. *J. Med. Microbiol.* **58**, 1133-1148.
- TENOVER F.C., ARBEIT R.D., GOERING R.V., MICKELSEN P.A., MURRAY B.E., PERSING D.H., SWAMINATHAN B. (1995). Interpreting chromosomal DNA restriction patterns produced by pulsed-field gel electrophoresis: criteria for bacterial strain typing. *J. Clin. Microbiol.* **33**, 2233-2239.
- WALSH T.R., TOLEMAN M.A., POIREL L., NORDMANN P. (2002). Metallo-β-Lactamases: the quiet before the storm? *J. Clin. Microbiol.* **18**, 3798-3801.
- YAN J.J., HSUEH P.R., KO W.C., LUH K.T., TSAI S.H., WU H.M., WU J.J. (2001). Metallo-β-lactamase in clinical isolates of *Pseudomonas* isolates in Taiwan and identification of VIM-3, a novel variant of the VIM-2 enzyme. *Antimicrob. Agents. Chemother.* **45**, 2224-2228.
- YATSUYANAGI J., SAITO S., HARATA S., SUZUKI N., ITO Y., AMANO K., ENOMOTO K. (2004). Class 1 integron containing metallo-β-lactamase gene *bla*_{VIM-2} in *Pseudomonas aeruginosa* clinical strains isolated in Japan. *Antimicrob. Agents. Chemother.* **48**, 26-628.